RankingsPricing
  1. US-listed companies
  2. Ovid Therapeutics Inc.
  3. Financials
  4. Research & development

Ovid Therapeutics Inc.OVID

Market cap
$105.24M
P/E ratio
SummaryFinancials
Period EndResearch & development (Million USD)YoY (%)
Dec 31, 202437+28.61%
Dec 31, 202329+16.12%
Dec 31, 202225-47.55%
Dec 31, 202147-25.98%
Dec 31, 202063+50.43%
Dec 31, 201942+24.76%
Dec 31, 201834-32.38%
Dec 31, 201750

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating income Operating expenses Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSAdjusted EPSDividend payout ratio (%)Dividend per shareAdjusted DPSEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)